Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

(2012) W. Leung et al.   BLOOD

Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia

(2012) S A Buckley et al.   BONE MARROW TRANSPLANTATION

Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories

(2012) Jan J. Cornelissen et al.   JOURNAL OF CLINICAL ONCOLOGY

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

(2012) Jan J. Cornelissen et al.   Nature Reviews Clinical Oncology

Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia

(2012) Betty K. Hamilton et al.   STEM CELLS

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

(2011) W. Leung et al.   BLOOD

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

(2011) F. Buccisano et al.   BLOOD

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Graft-versus-disease effect following allogeneic transplantation for acute leukaemia

(2008) Jacob M. Rowe   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia

(2008) Luca Maurillo et al.   JOURNAL OF CLINICAL ONCOLOGY